Cargando…
Recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma
OBJECTIVE: To describe recovery of adrenal insufficiency in asthmatic children treated with inhaled corticosteroids (ICS) and cortisol replacement therapy. DESIGN: Retrospective, observational study. PATIENTS: A total of 113 patients, 74 male; age 10.4 (3.3–16.5) years; beclomethasone-equivalent ICS...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735982/ https://www.ncbi.nlm.nih.gov/pubmed/29290688 http://dx.doi.org/10.2147/JAA.S142874 |
_version_ | 1783287308768772096 |
---|---|
author | Gangadharan, Arundoss McCoy, Paul Phyo, Aye McGuigan, Michael P Dharmaraj, Poonam Ramakrishnan, Renuka McNamara, Paul S Blair, Joanne |
author_facet | Gangadharan, Arundoss McCoy, Paul Phyo, Aye McGuigan, Michael P Dharmaraj, Poonam Ramakrishnan, Renuka McNamara, Paul S Blair, Joanne |
author_sort | Gangadharan, Arundoss |
collection | PubMed |
description | OBJECTIVE: To describe recovery of adrenal insufficiency in asthmatic children treated with inhaled corticosteroids (ICS) and cortisol replacement therapy. DESIGN: Retrospective, observational study. PATIENTS: A total of 113 patients, 74 male; age 10.4 (3.3–16.5) years; beclomethasone-equivalent ICS dose, 800 μg, (100–1,000), tested by low dose short Synacthen (tetracosactide) test (LDSST), were studied. Test results were classified by basal and peak cortisol concentration: “normal” (basal >100 nmol/L, peak >500 nmol/L), “suboptimal” (basal >100 nmol/L, peak 350–499 nmol/L), “abnormal” (basal <100 nmol/L and/or peak <350 nmol/L). Patients with suboptimal results received hydrocortisone during periods of stress only, and those with abnormal responses received daily hydrocortisone, increased during periods of stress. A total of 73 patients (68%) had ≥2 LDSSTs over 2.2 years (0.2–7.7). MEASUREMENTS: Change in cortisol response to repeat LDSST (movement between diagnostic groups, difference in basal and peak cortisol >15% [2× the inter-assay coefficient of variation]), change in BMI and height standard deviation score (SDS). RESULTS: Baseline test results were abnormal in 17 patients (15%) and all of them had repeat tests. In 13 patients (76%), test results improved (normal in six, suboptimal in seven) and four (24%) remained abnormal. Baseline tests results were suboptimal in 54 patients (48%), of whom 50 (93%) were retested. Repeat tests were normal in 36 patients (72%), remained suboptimal in 11 (22%), and were abnormal in three (6%). Baseline tests results were normal in 42 patients, of whom six patients (14%) were retested. Results remained normal in three (50%), were suboptimal in two (33%), and abnormal in one (17%). Basal and peak cortisol levels increased by >15% in 33/73 (45%) and 42/73 (57%) patients, respectively, and decreased by >15% in 14/73 (19%) and 7/73 (10%), respectively. There was no significant change in height or BMI SDS. CONCLUSION: Recovery of adrenal function is common and occurs during continued ICS and cortisol replacement therapy. |
format | Online Article Text |
id | pubmed-5735982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-57359822017-12-29 Recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma Gangadharan, Arundoss McCoy, Paul Phyo, Aye McGuigan, Michael P Dharmaraj, Poonam Ramakrishnan, Renuka McNamara, Paul S Blair, Joanne J Asthma Allergy Original Research OBJECTIVE: To describe recovery of adrenal insufficiency in asthmatic children treated with inhaled corticosteroids (ICS) and cortisol replacement therapy. DESIGN: Retrospective, observational study. PATIENTS: A total of 113 patients, 74 male; age 10.4 (3.3–16.5) years; beclomethasone-equivalent ICS dose, 800 μg, (100–1,000), tested by low dose short Synacthen (tetracosactide) test (LDSST), were studied. Test results were classified by basal and peak cortisol concentration: “normal” (basal >100 nmol/L, peak >500 nmol/L), “suboptimal” (basal >100 nmol/L, peak 350–499 nmol/L), “abnormal” (basal <100 nmol/L and/or peak <350 nmol/L). Patients with suboptimal results received hydrocortisone during periods of stress only, and those with abnormal responses received daily hydrocortisone, increased during periods of stress. A total of 73 patients (68%) had ≥2 LDSSTs over 2.2 years (0.2–7.7). MEASUREMENTS: Change in cortisol response to repeat LDSST (movement between diagnostic groups, difference in basal and peak cortisol >15% [2× the inter-assay coefficient of variation]), change in BMI and height standard deviation score (SDS). RESULTS: Baseline test results were abnormal in 17 patients (15%) and all of them had repeat tests. In 13 patients (76%), test results improved (normal in six, suboptimal in seven) and four (24%) remained abnormal. Baseline tests results were suboptimal in 54 patients (48%), of whom 50 (93%) were retested. Repeat tests were normal in 36 patients (72%), remained suboptimal in 11 (22%), and were abnormal in three (6%). Baseline tests results were normal in 42 patients, of whom six patients (14%) were retested. Results remained normal in three (50%), were suboptimal in two (33%), and abnormal in one (17%). Basal and peak cortisol levels increased by >15% in 33/73 (45%) and 42/73 (57%) patients, respectively, and decreased by >15% in 14/73 (19%) and 7/73 (10%), respectively. There was no significant change in height or BMI SDS. CONCLUSION: Recovery of adrenal function is common and occurs during continued ICS and cortisol replacement therapy. Dove Medical Press 2017-12-15 /pmc/articles/PMC5735982/ /pubmed/29290688 http://dx.doi.org/10.2147/JAA.S142874 Text en © 2017 Gangadharan et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Gangadharan, Arundoss McCoy, Paul Phyo, Aye McGuigan, Michael P Dharmaraj, Poonam Ramakrishnan, Renuka McNamara, Paul S Blair, Joanne Recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma |
title | Recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma |
title_full | Recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma |
title_fullStr | Recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma |
title_full_unstemmed | Recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma |
title_short | Recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma |
title_sort | recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735982/ https://www.ncbi.nlm.nih.gov/pubmed/29290688 http://dx.doi.org/10.2147/JAA.S142874 |
work_keys_str_mv | AT gangadharanarundoss recoveryofhypothalamopituitaryadrenalaxissuppressionduringtreatmentwithinhaledcorticosteroidsforchildhoodasthma AT mccoypaul recoveryofhypothalamopituitaryadrenalaxissuppressionduringtreatmentwithinhaledcorticosteroidsforchildhoodasthma AT phyoaye recoveryofhypothalamopituitaryadrenalaxissuppressionduringtreatmentwithinhaledcorticosteroidsforchildhoodasthma AT mcguiganmichaelp recoveryofhypothalamopituitaryadrenalaxissuppressionduringtreatmentwithinhaledcorticosteroidsforchildhoodasthma AT dharmarajpoonam recoveryofhypothalamopituitaryadrenalaxissuppressionduringtreatmentwithinhaledcorticosteroidsforchildhoodasthma AT ramakrishnanrenuka recoveryofhypothalamopituitaryadrenalaxissuppressionduringtreatmentwithinhaledcorticosteroidsforchildhoodasthma AT mcnamarapauls recoveryofhypothalamopituitaryadrenalaxissuppressionduringtreatmentwithinhaledcorticosteroidsforchildhoodasthma AT blairjoanne recoveryofhypothalamopituitaryadrenalaxissuppressionduringtreatmentwithinhaledcorticosteroidsforchildhoodasthma |